Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Boehringer Mannheim reports fibrinogen antagonists for thromboembolic conditions

Oct. 4, 1996

Joint venture formed for development of oral heparin

Oct. 4, 1996

Interim phase II results reported for Neutralase

Oct. 4, 1996

Gensia and Microbix agreement for generic urokinase alternative

Sep. 27, 1996

Tanabe reports t-PA-enhancing compounds

Sep. 27, 1996

gpIIb/IIIa antagonist selected for clinical evaluation at DuPont Merck

Sep. 27, 1996

DuPont Merck proposes new standards for warfarin products

Sep. 27, 1996

Thrombin inhibitors with improved selectivity from Servier

Sep. 27, 1996

Antiplatelet ketoprofen analogue from Fuji Chem.

Sep. 20, 1996

Bristol-Myers Squibb to acquire prostacyclin analogue for claudication

Sep. 20, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...